Register HomeChinese Version Lychee Group Register


FOUNDERS

Founding Individuals

line

Dr. Frank KungFrank Kung
Managing Partner, Vivo Capital



Dr. Kung is a founding member of Vivo Capital (formerly BioAsia Investments), a healthcare/biotechnology venture capital management firm in Palo Alto, California.

Dr. Kung started his career in the biotechnology industry in 1979 when he joined Cetus Corporation. He later co-founded Cetus Immune Corporation in 1981, which was acquired by its parent company in 1983. In 1984 he co-founded Genelabs Technologies, Inc. (NADSAQ: GNLB) where he served as Chairman and CEO until 1995. During his tenure in Genelabs, he brought the company public in 1991, and built it to a 175 employee international biotech company with operations in the United States, Belgium, Singapore, Switzerland and Taiwan.

Dr. Kung received his B.S. in chemistry from the National Tsing Hua University in Taiwan, his Ph.D. in molecular biology and M.B.A. from the University of California, Berkeley. He received the Best Use of Technology Award from the Governor of California, the Entrepreneur of the Year Awards from Ernst and Young, and the Asian Business League. He also served on the board of directors of the Emerging Company Governing Body of the Biotechnology Industry Organization (BIO); Mt. Jade Science and Technology Association, West Coast; and the Asian American Manufacturing Association. He was appointed by the U.S. Secretary of Health and Human Services as a voting member of the National Biotechnology Policy Board. Dr. Kung currently serves on the board of directors of a number of emerging healthcare and biotechnology companies.

 

Hongbo LuHongbo Lu
Managing Director, Asia Public Equity, Orbimed



Dr. Hongbo Lu is a Managing Director of OrbiMed Asia, responsible for public equity and late stage investment in the region. Previously, Dr. Lu was a Principal at Piper Jaffray & Co. where she led Pipers China healthcare research team and was instrumental in building the firm's brand in the Asian marketplace. Prior to her Wall Street career, Dr. Lu spent four years in life science start-up operations and business development at Zyomyx, Inc. Dr. Lu received a Ph.D. in BioEngineering from the University of Washington, an M.B.A. from the Haas School of Business at the University of California, Berkeley, and a B.S./M.S. in Materials Science and Engineering from Tsinghua University in China. Dr. Lu currently serves as board of directors of Crown Bioscience and PharmAbcine (Korea).

 

James Li M.D.James Li
CEO, JW Therapeutics



Currently James has been focusing on investing and building new life science companies that brings in cross-board breakthrough technologies and disruptive business models in China.

Until June 2015, Dr. James Li was a Vice President and the founding General Manager of Amgen China, where he led the company’s efforts in formulating a China entry strategy and established its presence in China to help patients gaining access to Amgen’s vital medicines.

Prior to joining Amgen, James was a Partner at Kleiner Perkins Caufield & Byers life science practice, worked both in the US and China funds. He successfully invested in a number of companies both in the US and China.

From 1991 to 2006, James spent over 15 years with Merck Co. & Inc. where he held leadership positions with increasing responsibilities in clinical research, regulatory affairs, new product development and franchise management, both in the US and Asia Pacific/China. During his tenure, he was instrumental in obtaining regulatory approvals of Merck vaccines across Asia Pacific Region when the Vaccine Division started operations in the region, successfully built the foundations of Merck’s medical operations in China and drove the success of Merck’s anti-hypertension franchise in Asia.

James received his Medical Degree from Shanghai Medical University followed by a Master of Science degree in Microbiology from the University of Montana.

 

Norman ChenNorman Chen
Venture Partner, Eight Roads Ventures


Mr. Norman Chen has over 20 years of experience as a senior executive, entrepreneur and venture capitalist in the healthcare industry.

He began his healthcare career at Baxter International, where he was responsible for the dialysis products business unit across 13 markets in Asia. Mr. Chen founded Asia Renal Care and led the company’s growth to become the leading independent dialysis provider in Asia with over 70 dialysis centers in Taiwan, Singapore, Philippines, Japan, Korea and Malaysia.

In 2002, Mr. Chen joined Walden International as Entrepreneur-in-Residence. From 2005-2012, he led the healthcare venture capital investments for Fidelity Growth Partners Asia (now called Eight Roads Ventures), investing in several successful companies in the CRO, specialty pharmaceutical, medical device and medical services areas in China. He is currently a Co-Founder and Board Member of DeltaHealth, which is opening a 200-bed cardiovascular hospital in Shanghai in 2016.

Mr. Chen has a Bachelor of Science degree in Biology from MIT and an MBA from Stanford University. He resides in the SF Bay Area.

 

Marietta WuMarietta Wu
Chief Operating Officer, Zai Laboratory



Dr. Wu’s experience ranges from clinical medicine and medical research to finance and entrepreneurship. She is co-founder and COO of Zai Laboratory, a biotech company in China focusing on developing innovative medicine with global standards. Prior to that, she was Managing Director at Burrill & Company, where she led venture capital investing in China and Taiwan related life sciences opportunities, and served as an acting COO of Waterstone Pharmaceuticals, a specialty pharmaceutical company with key operations in China. In addition, she assists companies seeking trans-Pacific partnerships. Dr. Wu is a frequent speaker and author on China life sciences topics.

Prior to joining Burrill, Dr. Wu was Director of Strategy at Edwards Lifesciences. She also held various financial and business development positions at Eli Lilly & Company. In the past few years, she has been active in cross border ventures and value creation in the life sciences industry.

Dr. Wu received her medical degree from Shanghai Jiaotong University School of Medicine (formerly Shanghai Second Medical University), a Ph.D. in Medical Sciences from Medical College of Ohio, and an MBA from the University of Michigan Business School.

Organizing Committee

line
Norman ChenNorman Chen
Venture Partner, Eight Roads Ventures
Dr. Frank KungFrank Kung
Managing Partner, Vivo Capital
James Li M.D.James Li
CEO, JW Therapeutics
Hongbo Lu, Ph.D.Hongbo Lu
Managing Director, Asia Public Equity, Orbimed

Marietta WuMarietta Wu
Chief Operating Officer, Zai Laboratory

 

 

Cyber CaoCyber Cao
Managing Director, Vivo Capital


Cyber Cao, M.S., is a Managing Director based in Shanghai. Cyber joined Vivo with extensive healthcare experience. After joining Vivo in 2011, Cyber participated most of the Vivo Fund VII investment in China and currently serves on the board of SMC and Gengmei APP.

Prior to joining Vivo, Cyber was the leader of Nycomed North Asia strategy and business development. He helped Nycomed refurbish its China business and played an integral role in its acquisition of Techpool, a leading Chinese pharmaceutical player. Prior to Nycomed, Cyber was at McKinsey & Company where he worked with both multi-national and local pharmaceutical companies on corporate strategy. Mr. Cao received his M.S. in Pharmacy Administration and a B.S. in Pharmaceutics from Peking University.

 

Maykin HoMaykin Ho
Venture Partner, Qiming Venture Partners


Maykin joined Qiming as a venture partner in 2015. She is a retired Partner of Goldman Sachs & Co. where she spent 24 years, most recently as an Advisory Director for Global Healthcare Investment Banking. Previously, she was a biotechnology analyst and co-head of US Healthcare for Global Investment Research. Maykin was ranked the First or Second Team in Biotechnology by Institutional Investor and Greenwich Associates for over 10 years. She has also received numerous awards from The Wall Street Journal and Financial Times.

Prior to joining Goldman Sachs, Maykin held senior management positions in research, marketing and business development at Dupont-Merck Pharmaceuticals and Dupont De Nemours & Company.

Maykin is a member of the board of directors for Agios Pharmaceuticals, Parexel International and The Aaron Diamond AIDS Research Center, an affiliate of Rockefeller University. She has also served on the Investment Committee of the Society for Neuroscience as well as the Advisory Council of the Department of Biological Chemistry at Harvard Medical School.

 

Jon LiongJon Liong
Managing Director, Lychee Group


Jon is the Founder and Managing Partner of Lychee Group, a company focused on creating the highest-quality events for China's life sciences industry.

Jon brings over 15 years of success in the strategic planning, organization and marketing of pharmaceutical and biotech business-to- business conferences.

In 1999, he joined Strategic Research Institute, a leading New York- based conference company. During his tenure there he organized and directed over 100 successful life sciences conferences and managed the production of over 40 events annually. As Managing Director, Jon led the company’s global expansion into China, conceiving and launching the "IMPACT CHINA: Pharmaceutical Global R&D" series, which was the first ever Western-organized conference covering China's life sciences industry.

Since starting Lychee, Jon has helped launch some of the highest profile healthcare events in China including "China Healthcare Investment Conference (CHIC)," "ChinaTrials: Global Clinical Development Summit," and "Asia Healthcare CEO Meeting by OrbiMed."

Jon received his B.S. in Marketing from the New York University Stern School of Business.

 

Jasmine LuoJasmine Luo
Vice President and Managing Director, China Health Industry Capital Fund Management



Jasmine Luo and her team focus on investing in high-tech enterprises at the expansion stage in the China healthcare industry. Prior to joining CHIC, she worked in Shenyin & Wanguo Securities and was well known as one of the best healthcare analysts in China.

 

Karen WongKaren Wong
Partner, Wilson Sonsini Goodrich & Rosati



Dr. Karen Wong is a life sciences IP partner at Wilson Sonsini Goodrich & Rosati. Her practice includes freedom- to-operate and due-diligence studies, patent preparation and prosecution, opinion work, litigation strategy, and technology licensing. Karen serves as IP counsel to many venture-backed companies, and has worked on numerous major strategic alliance transactions, acquisitions, spin-outs, and IPOs.

Dr. Karen Wong is a life sciences IP partner at Wilson Sonsini Goodrich & Rosati. Her practice includes freedom- to-operate and due-diligence studies, patent preparation and prosecution, opinion work, litigation strategy, and technology licensing. Karen serves as IP counsel to many venture-backed companies, and has worked on numerous major strategic alliance transactions, acquisitions, spin-outs, and IPOs.

Prior to practicing law, Karen conducted doctoral and post-doctoral research at Harvard and Tufts Medical School in molecular biology, cell biology, and physiology.

Karen is a co-founder and board member of BioE2E, which has built one of the largest communities of life sciences entrepreneurs in the Bay Area. A native of Sichuan, China, she is fluent in English, Mandarin, and Cantonese.

 

Chen YuChen Yu
Managing Partner, Vivo Capital


Chen Yu, M.D., M.B.A. is a Managing Partner based in Palo Alto who joined Vivo in 2004. At Vivo, Dr. Yu invests in both private and public pharmaceutical and medical device companies in the US and China. Dr. Yu has extensive operating experience with leadership roles at both private and public companies, including Sagent Pharmaceuticals (SGNT), China KangHui (KH), and aQuantive (AQNT). Notably, Dr. Yu has played a leading industry role in facilitating cross border deals between emerging market and US healthcare companies. As Chief Business Officer at China KangHui (KH), a leading China based orthopedic company, he helped take the company public on the New York Stock Exchange in 2010 and ultimately led negotiations during the sale to Medtronic for $816 MM in 2012. Most recently, Dr. Yu served as Chief Operating Officer at Sagent Pharmaceuticals (SGNT), which partners with leading companies across Asia and Europe. Dr. Yu currently serves or has served on the boards of several life science companies in both the US and China, including Sentre Heart (US), Rempex (Acquired by MDCO), Nora Therapeutics (US), Jian Rui Bao (China), GMT Medical (China), and Synaptic Medical (China). Other representative investments include Trauson (acquired by Stryker for $764 MM), Durata (acquired by Actavis for $800 MM), Achillion (ACHN), Cubist (CBST), and Ocera (OCRX).

Dr. Yu is also active in the community and currently serves on the California Leadership Council for the Nature Conservancy, an environmental non-profit with global reach. He was also previously a member of the Stanford Medical School Alumni Board of Governors. Dr. Yu received his M.D. and M.B.A. from Stanford University and graduated magna cum laude with a B.A. in Biology from Harvard University.

Active Founding Organizations

line

Fidelity Asia Ventures   Vivo Ventures


Copyright © 2017 Consortium of China Healthcare. All rights reserved. Join Our Mailing List